Clinical Trial With MBK-01, Intestinal Microbiota Capsules, for the Treatment of Patients With Recurrent Diverticulitis

PHASE2RecruitingINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

April 3, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
DiverticulitisDiverticulitis of Sigmoid
Interventions
BIOLOGICAL

MBK-01

Initial dose of 4 capsules of MBK-01 (heterologous lyophilized intestinal microbiota coming from healthy donors) orally the first day, followed by a single daily capsule during 16 days. Participants will receive a total dose of 20 capsules of MBK-01.

BIOLOGICAL

MBK-01

Initial dose of 4 capsules of MBK-01 (heterologous lyophilized intestinal microbiota coming from healthy donors) orally the first day, followed by a single daily capsule for 16 days and a maintenance dose 3 months after the ending of the initial dose. The maintenance dose is administered the same as the initial dose: 4 capsules of MBK-01 orally the first day, followed by a single daily capsule for 16 days. Participants will receive a total dose of 40 capsules of MBK-01.

Trial Locations (1)

28034

RECRUITING

Hospital Universitario Ramón y Cajal, Madrid

All Listed Sponsors
lead

Mikrobiomik Healthcare Company S.L.

INDUSTRY